Lincoln Pharmaceuticals Ltd · NSE:LINCOLN
Lincoln Pharmaceuticals — Q2 FY2019 Earnings Presentation
20 slides from Lincoln Pharmaceuticals's earnings presentation, 2018
Slide 1: Q2 FY2019 Earnings Presentation
Q2 FY2019 Earnings Presentation Providing Affordable and Innovative medicines for healthier lives
Slide 2: Highlights
Highlights Q2 FY2019 vs. Q2 FY2018 Management Perspective “The company has shown the Profit Before Tax (PBT) of Rs. 46.24 Crs for the financial year ending as on 31.03.2018, as against company had achieved PBT o Total Income of Rs. 1,070.4 million, up 15.5% of Rs. 42.93 Crs for the period ending on
Slide 3: Performance Overview
Performance Overview Consolidated Financial Performance Q2 y-o-y Q1 q-o-q Half Year y-o-y Particulars FY2019 FY2018 Growth (%) FY2019 Growth (%) FY2019 FY2018 Growth (%) Net Revenue 1,070 926 15.5% 1,021 4.8% 2,092 2,450 (14.6)% EBITDA 235.2 184.2 27.7% 255.9 (8.1)% 491.1 282.8 73.6% Margin (%) 22.0
Slide 4: Quarterly Revenue Breakup
Performance Overview Quarterly Revenue Breakup 4% 2% 3% 2% General Anti Infectives 19.2% 9% 24% 21.0% 21.5% 26.1% Respiratory Systems Therapeutic Area 14%0.5% Alimentary Tract and Metabolism 0.5% 2.5% 2.8% Genito Urinary System and Sex Hormones 0.3% Q2 FY19 9.9% 2.9% 13% Q2 FY18 15% Musculo-Skeletal
Slide 5: Performance Trend
Performance Trend Total Income (Rs. million) and Y-o-Y Growth (%) Q2 FY2019 Highlights (Y-o-Y) 15.5% 18.1% 10.3% (33.0)% (43.8)% o The company has shown the Profit Before Tax (PBT) of Rs. 46.24 Crs for the financial 926.5 830.2 679.7 1,021.2 1,070.4 year ending as on 31.03.2018, as against this Q2 F
Slide 6: Performance Trend
Performance Trend Net Debt / LTM EBITDA Total Debt / Net Worth 1.87x 0.5x 1.0x 0.9x 0.2x 0.26x 0.68x 0.2x 0.18x 0.47x Q2 FY18 Q3 FY18 Q4 FY18 Q1 FY19 Q2 FY19 Q2 FY18 Q3 FY18 Q4 FY18 Q1 FY19 Q2 FY19 ROCE1 RONW2 24.3% 22.1% 19.0% 19.6% 16.7% 15.4% 14.5% 14.9% 13.0% 11.3% Q2 FY18 Q3 FY18 Q4 FY18 Q1 FY1
Slide 7: Leverage Profile
Leverage Profile (Rs. million) Sep 2018 Jun 2018 Long Term Debt 153 161 Credit Rating Short Term Debt 313 466 o The Company’s debt facilities have been assigned Total Debt 466 627 the following ratings by ICRA ▪ Long term bank facilities: A- Less: Cash & Cash Equivalents 100 126 ▪ Short term bank fa
Slide 8: Recent Developments
Recent Developments 1 Investment in renewable power to further enhance operational efficiency • Setting up a new Solar Plant of 1 MW at factory’s rooftop with a capacity of producing 15 Lakh Power Unit PA • The Plant will be operational from last quarter of this year 2 Setting up API production unit
Slide 9: Recent Developments
Recent Developments 5 Developed new NDDS formulation Ondansetron Oral Spray (Domi Up) for the first time in India • Currently the Ondansetron formulation is available in the form of tablet, syrup and injectable. Lincoln Pharma has developed Ondansetron (Domi Up) as an oral spray which is first in In
Slide 10: Research & Development
Research & Development Research Facilities R&D Expenditure (Rs. mn) and as % of Sales 3.2% 2.4% 2.0% 2.7% 117.3 Senior Scientist 15 1.6% 88.5 Junior Scientist 18 72.6 79.5 Analysts 18 Regulatory Personnel 12 34.3 Administrative Personnel 9 Others 6 Total 78 FY14 FY15 FY16 FY17 FY18 10
Slide 11: A Leading Pharmaceutical Company
A Leading Pharmaceutical Company Research & Development Department Market Presence Presence in Presence in 4 Patents Granted 1,000 Registered Dossiers 60+ 25 25 Patents Applications 550 Ongoing Applications Countries States across India 300+ 43rd 15+ Formulations Developed Rank in AIOCD Therapeutic
Slide 12: Key Milestones
Key Milestones Received WHO – Becomes Public Covered 80% Installed Windmill Developed & Launch 3 products which are GMP for plant / Limited Company of all India 600 KVA launched 2 more first time in India. Entered in production unit from a Partnership Market NDDS products more (regulated) African an
Slide 13: Global Footprint
Global Footprint Presence over 60 countries in Europe, Latin America, Africa, Asia Pacific and South East Asia; 22 states across India Jammu Uttaranchal Chandigarh Delhi Europe: Ambala Ghaziabad France Lucknow Guwahati Jaipur Patna Ranchi Ahmedabad Kolkata Indore Raipur Nagpur Cuttack Vijayawada Che
Slide 14: Best-in-Class Facilities
Best-in-Class Facilities Certifications: WHO-GMP Certified; ISO9001:2008 Certified R&D Center: Approved by Government of India; Team of 30 scientists for R&D Green Energy: Windmill project for captive consumption Dosage Forms Produced at Unit 1 Dosage Forms Produced at Unit 2 Description Annual Capa
Slide 15: Wide Spectrum of Therapeutic Coverage
Wide Spectrum of Therapeutic Coverage Cough & Cold / Sterile Ophthalmic Dermatologist Gyneacologial Gastro Intestinal Anti Allergic / Anti- Eye Preparation Products Range asthmatics Drops/Ointment Anti-bacterial / Vitamins / Minerals Analgesic / Anti- Anti-diuretics/ Anti-malarial Anti-viral/ Anti-
Slide 16: Key Brands
Key Brands Domestic Market International Market Calcium Carbonate 1250 mg+ 11 Antioxidants + 33 Essential Micronutrients + Each squirts (spray) delivers 2 Vit. D3 250 I.U. Tablets 5 Amino Acids mg Ondansetron Hydrochloride α-β Arteether Injection Artesunate for Injection 60 mg Anti Cold Capsules 150
Slide 17: Key Recent Developments
Key Recent Developments o Progesterone spray • Unique delivery system for accurate 25mg delivery of micronized progesterone/Spray • Formulation dispensed in mist form which provides local as well as systemic effect of Progesterone via vaginal route covering large area of vaginal cavity • Better pati
Slide 18: Key Recent Developments
Key Recent Developments o Arteether injection 150 mg/ml • Unique low-viscosity sterile formulation for malaria • Less painful and low volume (1 ml) IM formulation • Convenient patient administration • Patented technology o Namcold DX • First time in India: ‘Extended Release’ Oral Suspension • The on
Slide 19: Disclaimer
Disclaimer This presentation contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Lincoln Pharmaceuticals’ future business developments and economic perfor
Slide 20: Corporate Office
CORPORATE OFFICE LINCOLN HOUSE B/h. Satyam Complex, Science City Road, Sola, Ahmedabad – 380 062. Gujarat, INDIA. Phone :+91-79-67778000 • Fax:+91-79-67778062 E-mail:info@lincolnpharma.com www.lincolnpharma.co.in KP Sompura, Finance Head sompurakp@lincolnpharma.com Lincoln Pharmaceuticals +91 79 677
Lincoln Pharmaceuticals — Q2 FY2019 Earnings Presentation on 6ix